Jan 03, 2017 13:03 pm UTC| Business
NEW YORK, Jan. 03, 2017 -- Avenue Therapeutics, Inc. (“Avenue”), a Fortress Biotech (NASDAQ:FBIO) Company, today announced that Notices of Allowance have now been received from the U.S. Patent and Trademark Office...
Jan 03, 2017 13:03 pm UTC| Business
NEW YORK, Jan. 03, 2017 -- Avenue Therapeutics, Inc. (“Avenue”), a Fortress Biotech (NASDAQ:FBIO) Company, today announced that Notices of Allowance have now been received from the U.S. Patent and Trademark Office...
Jan 03, 2017 13:03 pm UTC| Business
NEW YORK, Jan. 03, 2017 -- Avenue Therapeutics, Inc. (“Avenue”), a Fortress Biotech (NASDAQ:FBIO) Company, today announced that Notices of Allowance have now been received from the U.S. Patent and Trademark Office...
Jan 03, 2017 13:03 pm UTC| Business
TEL AVIV, Israel, Jan. 03, 2017 -- Cellect Biotechnology Ltd. (Nasdaq:APOP) (TASE:APOP), a developer of innovative technology which enables the functional selection of stem cells, today announced that Mr. Eyal Leibovitz...
Jan 03, 2017 13:03 pm UTC| Business
TEL AVIV, Israel, Jan. 03, 2017 -- Cellect Biotechnology Ltd. (Nasdaq:APOP) (TASE:APOP), a developer of innovative technology which enables the functional selection of stem cells, today announced that Mr. Eyal Leibovitz...
Jan 03, 2017 13:03 pm UTC| Business
TEL AVIV, Israel, Jan. 03, 2017 -- Cellect Biotechnology Ltd. (Nasdaq:APOP) (TASE:APOP), a developer of innovative technology which enables the functional selection of stem cells, today announced that Mr. Eyal Leibovitz...
Jan 03, 2017 13:03 pm UTC| Business
TEL AVIV, Israel, Jan. 03, 2017 -- Cellect Biotechnology Ltd. (Nasdaq:APOP) (TASE:APOP), a developer of innovative technology which enables the functional selection of stem cells, today announced that Mr. Eyal Leibovitz...